Allele Biotechnology
Pre-clinicalNext-gen mRNA technologies enabling faster, cleaner, and highly efficient cell programming.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $10M
About
Next-gen mRNA technologies enabling faster, cleaner, and highly efficient cell programming.
Antibodies
Funding History
2Total raised:$10M
Series A$8MJun 15, 2013
Seed$2MJun 15, 2010